公开(公告)号：WO2016176756A1

公开(公告)日：2016-11-10

申请号：PCT/CA2015/051223

申请日：2015-11-24

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： KEATING, Armand ,  WILLIAMS, Brent Allen ,  WANG, Xing-Hua

IPC: A61K39/395 ,  A61K35/17 ,  A61P35/00 ,  A61P35/02

CPC classification number: A61K35/17 ,  A61K39/395 ,  A61K2039/505 ,  A61P35/02 ,  C07K16/2803 ,  C07K2317/732 ,  C12N5/00 ,  C12N5/0646

Abstract: Treatment of cancer in a patient comprises administering to the patient an effective amount of an antibody and an effective amount of NK cells, wherein the antibody binds an antigen on the surface of the NK cells and the antibody binds to an Fc receptor on a cell of the cancer. Anticancer activity is via resultant killing action of the NK cell on the cancer cell now binding the antibody via R-ADCC.

Abstract translation: 治疗患者的癌症包括向患者施用有效量的抗体和有效量的NK细胞，其中所述抗体结合NK细胞表面上的抗原，并且所述抗体与细胞上的Fc受体结合 癌症。 抗癌活性是通过NK细胞对目前通过R-ADCC结合抗体的癌细胞的杀伤作用。

公开(公告)号：WO2017137595A3

公开(公告)日：2017-08-17

申请号：PCT/EP2017/053061

申请日：2017-02-10

Applicant: ONKOCELLULAR LIMITED ,  UNIVERSITY HEALTH NETWORK

Inventor： KEATING, Armand ,  WILLIAMS, Brent, Allen ,  WANG, Xing-Hua ,  O'DWYER, Michael, Eamon, Peter ,  SCHLICH, George, William

IPC: C07K16/28 ,  A61K39/395 ,  A61K35/17 ,  A61P35/02 ,  A61K39/00

Abstract: Treatment of cancer in a patient comprises administering to the patient an antibody and a non-antibody agent that activates the patient's own NK cells, wherein the antibody binds an antigen on the surface of the patient's own NK cells and the antibody Fc region binds to an Fc receptor on a cell of the cancer. Anticancer activity is via resultant killing action of the NK cell on the cancer cell, now binding the antibody Fc region, via reverse antibody-dependent cell-mediated cytotoxicity (R-ADCC).

Abstract translation: 治疗患者中的癌症包括向患者施用激活患者自身NK细胞的抗体和非抗体剂，其中所述抗体结合患者自身NK细胞表面上的抗原 并且抗体Fc区与癌细胞上的Fc受体结合。 抗癌活性是通过经由反向抗体依赖性细胞介导的细胞毒性（R-ADCC）现在结合抗体Fc区的NK细胞对癌细胞的杀伤作用产生的。

公开(公告)号：WO2017137595A2

公开(公告)日：2017-08-17

申请号：PCT/EP2017/053061

申请日：2017-02-10

Applicant: ONKOCELLULAR LIMITED ,  UNIVERSITY HEALTH NETWORK

Inventor： KEATING, Armand ,  WILLIAMS, Brent, Allen ,  WANG, Xing-Hua ,  O'DWYER, Michael, Eamon, Peter ,  SCHLICH, George, William

IPC: C07K16/28 ,  A61K39/395 ,  A61K35/17 ,  A61P35/02

CPC classification number: A61K35/17 ,  A61K31/00 ,  A61K39/39541 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2851 ,  C07K2317/732 ,  C07K2317/92 ,  A61K2300/00

Abstract: Treatment of cancer in a patient comprises administering to the patient an antibody and a non-antibody agent that activates the patient's own NK cells, wherein the antibody binds an antigen on the surface of the patient's own NK cells and the antibody Fc region binds to an Fc receptor on a cell of the cancer. Anticancer activity is via resultant killing action of the NK cell on the cancer cell, now binding the antibody Fc region, via reverse antibody-dependent cell-mediated cytotoxicity (R-ADCC).

Abstract translation: 治疗患者中的癌症包括向患者施用激活患者自身NK细胞的抗体和非抗体剂，其中所述抗体结合患者自身NK细胞表面上的抗原 并且抗体Fc区与癌细胞上的Fc受体结合。 抗癌活性是通过经由反向抗体依赖性细胞介导的细胞毒性（R-ADCC）现在结合抗体Fc区的NK细胞对癌细胞的杀伤作用产生的。

公开(公告)号：EP3291833A1

公开(公告)日：2018-03-14

申请号：EP15891040.6

申请日：2015-11-24

Applicant: University Health Network

Inventor： KEATING, Armand ,  WILLIAMS, Brent Allen ,  WANG, Xing-Hua

IPC: A61K39/395 ,  A61K35/17 ,  A61P35/00 ,  A61P35/02

CPC classification number: A61K35/17 ,  A61K39/395 ,  A61K2039/505 ,  A61P35/02 ,  C07K16/2803 ,  C07K2317/732 ,  C12N5/0646

Abstract: Treatment of cancer in a patient comprises administering to the patient an effective amount of an antibody and an effective amount of NK cells, wherein the antibody binds an antigen on the surface of the NK cells and the antibody binds to an Fc receptor on a cell of the cancer. Anticancer activity is via resultant killing action of the NK cell on the cancer cell now binding the antibody via R-ADCC.